An Overview of nano delivery systems for targeting RNA interference-based therapy in ulcerative colitis

Iman Alfagih; Basmah Aldosari; Bushra Alquadeib; Alanood Almurshedi; Murtaza Tambuwala

doi:10.2174/1381612827666210617120302

An Overview of nano delivery systems for targeting RNA interference-based therapy in ulcerative colitis

Iman Alfagih, Basmah Aldosari, Bushra Alquadeib, Alanood Almurshedi, Murtaza Tambuwala

Research output: Contribution to journal › Review article › peer-review

1 Citation (Scopus)

17 Downloads (Pure)

Abstract

Ulcerative colitis (UC) is one of the main subtypes of inflammatory bowel disease. UC has a negative effect on patients’ quality of life, and it is an important risk factor for the development of colitis-associated cancer. Patients with UC need to take medications for their entire life because no permanent cure is available. Therefore, approaches that target messenger RNA (mRNA) of proinflammatory cytokines and/or anti-inflammatory cytokines are needed to improve the safety of UC therapy and promote intestinal mucosa recovery. The major challenge facing RNA interference-based therapy is the delivery of RNA molecules to the intracellular space of target cells. Moreover, nonspecific and systemic protein expression inhibition can result in adverse effects and low therapeutic benefit. Thus, it is important to develop an efficient delivery strategy targeting the cytoplasm of target cells to avoid side effects caused by off-target protein expression inhibition. This review focuses on the most recent advances in the targeted nano delivery systems of siRNAs and mRNA that have shown in vivo efficacy.

Original language	English
Pages (from-to)	2904-2914
Number of pages	11
Journal	Current Pharmaceutical Design
Volume	27
Issue number	25
DOIs	https://doi.org/10.2174/1381612827666210617120302
Publication status	Published (in print/issue) - 26 Aug 2021

Bibliographical note

Funding Information:
This research project was supported by a grant from the ?Research Center of the Female Scientific and Medical Colleges?, Deanship of Scientific Research, King Saud University, Saudi Arabia.

Funding Information:
This research project was supported by a grant from the “Research Center of the Female Scientific and Medical Colleges”, Deanship of Scientific Research, King Saud University, Saudi Arabia.

Publisher Copyright:
© 2021 Bentham Science Publishers.

Keywords

drug delivery system
colitis
RNA nanoparticles
Pharmaceutical Science
inflammation
Therapeutic
Nanoparticles
Surface functionalization
RNA interference
Targeted delivery
Inflammation
Ulcerative colitis
Intestinal Mucosa
Humans
RNA Interference
Colitis, Ulcerative/drug therapy
Quality of Life
RNAi Therapeutics

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2174/1381612827666210617120302

Revised_ManuscriptAuthor Accepted Manuscript, 153 KB

https://pubmed.ncbi.nlm.nih.gov/34139976/

Cite this

@article{50cf30e4154147808fb155fcfc146ecf,

title = "An Overview of nano delivery systems for targeting RNA interference-based therapy in ulcerative colitis",

abstract = "Ulcerative colitis (UC) is one of the main subtypes of inflammatory bowel disease. UC has a negative effect on patients{\textquoteright} quality of life, and it is an important risk factor for the development of colitis-associated cancer. Patients with UC need to take medications for their entire life because no permanent cure is available. Therefore, approaches that target messenger RNA (mRNA) of proinflammatory cytokines and/or anti-inflammatory cytokines are needed to improve the safety of UC therapy and promote intestinal mucosa recovery. The major challenge facing RNA interference-based therapy is the delivery of RNA molecules to the intracellular space of target cells. Moreover, nonspecific and systemic protein expression inhibition can result in adverse effects and low therapeutic benefit. Thus, it is important to develop an efficient delivery strategy targeting the cytoplasm of target cells to avoid side effects caused by off-target protein expression inhibition. This review focuses on the most recent advances in the targeted nano delivery systems of siRNAs and mRNA that have shown in vivo efficacy.",

keywords = "drug delivery system, colitis, RNA nanoparticles, Pharmaceutical Science, inflammation, Therapeutic, Nanoparticles, Surface functionalization, RNA interference, Targeted delivery, Inflammation, Ulcerative colitis, Intestinal Mucosa, Humans, RNA Interference, Colitis, Ulcerative/drug therapy, Quality of Life, RNAi Therapeutics",

author = "Iman Alfagih and Basmah Aldosari and Bushra Alquadeib and Alanood Almurshedi and Murtaza Tambuwala",

note = "Funding Information: This research project was supported by a grant from the ?Research Center of the Female Scientific and Medical Colleges?, Deanship of Scientific Research, King Saud University, Saudi Arabia. Funding Information: This research project was supported by a grant from the “Research Center of the Female Scientific and Medical Colleges”, Deanship of Scientific Research, King Saud University, Saudi Arabia. Publisher Copyright: {\textcopyright} 2021 Bentham Science Publishers.",

year = "2021",

month = aug,

day = "26",

doi = "10.2174/1381612827666210617120302",

language = "English",

volume = "27",

pages = "2904--2914",

journal = "Current Pharmaceutical Design",

issn = "1381-6128",

publisher = "Bentham Science ",

number = "25",

}

TY - JOUR

T1 - An Overview of nano delivery systems for targeting RNA interference-based therapy in ulcerative colitis

AU - Alfagih, Iman

AU - Aldosari, Basmah

AU - Alquadeib, Bushra

AU - Almurshedi, Alanood

AU - Tambuwala, Murtaza

N1 - Funding Information: This research project was supported by a grant from the ?Research Center of the Female Scientific and Medical Colleges?, Deanship of Scientific Research, King Saud University, Saudi Arabia. Funding Information: This research project was supported by a grant from the “Research Center of the Female Scientific and Medical Colleges”, Deanship of Scientific Research, King Saud University, Saudi Arabia. Publisher Copyright: © 2021 Bentham Science Publishers.

PY - 2021/8/26

Y1 - 2021/8/26

N2 - Ulcerative colitis (UC) is one of the main subtypes of inflammatory bowel disease. UC has a negative effect on patients’ quality of life, and it is an important risk factor for the development of colitis-associated cancer. Patients with UC need to take medications for their entire life because no permanent cure is available. Therefore, approaches that target messenger RNA (mRNA) of proinflammatory cytokines and/or anti-inflammatory cytokines are needed to improve the safety of UC therapy and promote intestinal mucosa recovery. The major challenge facing RNA interference-based therapy is the delivery of RNA molecules to the intracellular space of target cells. Moreover, nonspecific and systemic protein expression inhibition can result in adverse effects and low therapeutic benefit. Thus, it is important to develop an efficient delivery strategy targeting the cytoplasm of target cells to avoid side effects caused by off-target protein expression inhibition. This review focuses on the most recent advances in the targeted nano delivery systems of siRNAs and mRNA that have shown in vivo efficacy.

AB - Ulcerative colitis (UC) is one of the main subtypes of inflammatory bowel disease. UC has a negative effect on patients’ quality of life, and it is an important risk factor for the development of colitis-associated cancer. Patients with UC need to take medications for their entire life because no permanent cure is available. Therefore, approaches that target messenger RNA (mRNA) of proinflammatory cytokines and/or anti-inflammatory cytokines are needed to improve the safety of UC therapy and promote intestinal mucosa recovery. The major challenge facing RNA interference-based therapy is the delivery of RNA molecules to the intracellular space of target cells. Moreover, nonspecific and systemic protein expression inhibition can result in adverse effects and low therapeutic benefit. Thus, it is important to develop an efficient delivery strategy targeting the cytoplasm of target cells to avoid side effects caused by off-target protein expression inhibition. This review focuses on the most recent advances in the targeted nano delivery systems of siRNAs and mRNA that have shown in vivo efficacy.

KW - drug delivery system

KW - colitis

KW - RNA nanoparticles

KW - Pharmaceutical Science

KW - inflammation

KW - Therapeutic

KW - Nanoparticles

KW - Surface functionalization

KW - RNA interference

KW - Targeted delivery

KW - Inflammation

KW - Ulcerative colitis

KW - Intestinal Mucosa

KW - Humans

KW - RNA Interference

KW - Colitis, Ulcerative/drug therapy

KW - Quality of Life

KW - RNAi Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=85115654387&partnerID=8YFLogxK

U2 - 10.2174/1381612827666210617120302

DO - 10.2174/1381612827666210617120302

M3 - Review article

C2 - 34139976

SN - 1381-6128

VL - 27

SP - 2904

EP - 2914

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

IS - 25

ER -

An Overview of nano delivery systems for targeting RNA interference-based therapy in ulcerative colitis

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this